This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Sarepta's Next Step: Early FDA Approval

On the negative side, you can't dismiss the risk that comes from a tiny study of just 12 patients. The data are not pristine -- remember the two patients in the 30 mg eteplirsen dose who were excluded from the analysis because they experienced rapid declines in walking ability. FDA may simply conclude that more clinical data is needed for approval.

Manufacturing could be an issue. It's something investors often overlook but remember FDA can't approve a drug unless reliable manufacturing at commercial scale is in place. Sarepta is right now working on ramping up its eteplirsen manufacturing capacity but this process takes time. If there are delays in manufacturing scale-up, approval could be delayed.

Sarepta does face competition from a similar drug developed by GlaxoSmithKline (GSK - Get Report) and a partner in a phase III study. We should see results from this study relatively soon. A key question will be safety. The Glaxo DMD drug has shown some evidence of kidney toxicity in the past. If that persists, Sarepta's eteplirsen could be deemed superior.

Are there unresolved risks to the Sarepta story? Sure. Are these risks small next to the stellar eteplirsen data announced Wednesday and the $400-500 million market opportunity for the drug in the U.S.? Absolutely.

-- Reported by Adam Feuerstein in Boston.

Adam Feuerstein writes regularly for TheStreet. In keeping with company editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.
2 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
GSK $46.69 1.17%
SRPT $14.29 7.61%
AAPL $124.25 -0.14%
FB $81.66 -0.67%
GOOG $542.56 -0.99%


DOW 17,698.18 -77.94 -0.44%
S&P 500 2,059.69 -8.20 -0.40%
NASDAQ 4,880.2280 -20.6570 -0.42%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs